Company intelligence / Profile preview

Hefei HankeMab Biotechnology

Ownership: Private
Development stage: Other

Overview

Pipeline includes novel monoclonal and bispecific antibodies, with lead assets in Phase 1 and Phase 2 targeting cancer including non-Hodgkin lymphoma and HER2-positive gastric cancer. ZG033, a 4-1BB agonist mAb, received NMPA IND approval in 2024 and is in Phase 1. Recombinant anti-HER2 humanized HuA21 mAb is in Phase 2 for HER2-positive cancers. Bispecific candidates and fusion proteins are in preclinical and clinical evaluation, spanning hematologic and solid tumor indications. Most programs are in early- to mid-stage clinical development with no reported pivotal trial results yet.[2][3]

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBispecific antibodyAntibody fusion proteins
Industry: Biotech

Drug pipeline

3 assets

HuA21

2 more assets in the full pipeline.

Partnerships

Zencore Biologics

Beyond the preview

Go deeper on Hefei HankeMab Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hefei HankeMab Biotechnology.